Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

NCT06393751 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06393751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06393751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 31, 2025
Completion date
February 9, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-refractory fallopian tube carcinoma, platinum-refractory ovarian carcinoma, platinum-refractory primary peritoneal carcinoma, recurrent fallopian tube adenocarcinoma, recurrent fallopian tube carcinosarcoma, recurrent fallopian tube clear cell adenocarcinoma, recurrent fallopian tube high grade serous adenocarcinoma, recurrent fallopian tube undifferentiated carcinoma, recurrent high grade endometrioid adenocarcinoma, recurrent ovarian adenocarcinoma, recurrent ovarian carcinosarcoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian high grade serous adenocarcinoma, recurrent ovarian seromucinous carcinoma, recurrent ovarian undifferentiated carcinoma, recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent platinum-resistant primary peritoneal carcinoma, recurrent primary peritoneal adenocarcinoma, recurrent primary peritoneal carcinosarcoma, recurrent primary peritoneal clear cell adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma, recurrent primary peritoneal undifferentiated carcinoma